Navigation Links
Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:2/8/2011

all arteriovenous (AV) grafts require re-intervention after one year.(1,2) AV access failure is the most common reason for hospitalization among hemodialysis patients and can lead to anemia, infection, weight loss, jaundice, prolonged bleeding, and other serious complications.(3)

Vascugel – Combating Inflammation and Promoting HealingPervasis' novel approach to cell therapy uses adult-differentiated allogeneic endothelial cells (donor endothelial cells with a highly targeted biologic function) embedded in a patented polymer matrix to enhance the body's natural healing response. The endothelium is the thin layer of cells that lines the interior surface of blood vessels in the body. Endothelial cells are critical to tissue repair and health, and have a well-understood role in regulating many of the body's healing processes, including those associated with vascular repair.

Vascugel, which utilizes Pervasis' patented endothelial cell-based platform, is placed on the outside of the blood vessel at the AV access site during the surgical intervention to create the AV access point. The endothelial formulations in Vascugel secrete several factors that combat inflammation and promote proper vascular healing, reducing thrombosis (or clotting) and the formation of intimal hyperplasia, or a thickening of the blood vessel wall in response to injury. After approximately four to eight weeks, Vascugel is safely resorbed by the body.

The company's other areas of clinical investigation include improving outcomes in patients with peripheral artery disease (PAD) following surgical procedures such as percutaneous transluminal angioplasties (PTAs) with stenting, the failures of which result in serious complications and a significant increase in medical costs. Last month, Pervasis announced it has also embarked on an oncology development program using its proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metasta
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
2. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
3. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
4. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
5. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
6. China Medicine Corporation Receives Manufacturing License for rADTZ
7. Johnson & Johnson Receives Approval from European Commission
8. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
9. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
10. China Sky One Medical Receives Medical Industry Awards
11. Lakewood-Amedex Inc. Receives Notice of Allowance on Three US Patent Applications Relating to Treatment of Hemolytic Uremic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
(Date:8/28/2014)... 28, 2014 Amgen (NASDAQ: AMGN ... Application (BLA) to the U.S. Food and Drug Administration ... high cholesterol. Evolocumab is an investigational fully human monoclonal ... a protein that reduces the liver,s ability to remove ... blood. 1 ­ The ...
(Date:8/28/2014)... , Aug. 28, 2014  Rx Safes, Inc., ... announced that it is waging a new war on ... national media campaign. More than 2,500 children ... time and these drugs are easily accessed from unsecured medicine ... drug dealers on the streets, Rx Safes will address ...
Breaking Medicine Technology:ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9Rx Safes, Inc. Announces New War On Drugs 2
... , SARASOTA, Fla. , Jan. 15 ... its Senior Subordinated Convertible Notes due 2034 (CUSIP No. 776696AA4) (the "Notes") ... to July 15, 2010 at an annual rate of ... trading days ended July 13, 2010 . Contingent cash interest, which ...
... , SCOTTSDALE, Ariz. , Jan. 15 ... pharmaceutical competitive intelligence and market research, has published a ... therapies to treat hematologic malignancies.  These reports are based ... America immediately following the American Society of Hematology ...
Cached Medicine Technology:New MedPredict Report Highlights Recent Advances in Management of Malignant Hematology 2
(Date:8/28/2014)... 28, 2014 ABC television stars will ... MDA Show of Strength Telethon airing Sunday, Aug. 31, ... help raise funds and awareness to help save and ... muscle disease. , Viewers tuning into the 2014 telethon ... appeals and introductions from some of the network’s leading ...
(Date:8/28/2014)... 28, 2014 Biotronic, a Great Point ... neurophysiology monitoring ("IONM") company, today announced the promotion of ... Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic ... CFO in 2013 and has been an integral part ... efforts and achievements since joining the company in 2010 ...
(Date:8/28/2014)... 2014 Allegheny Health Network ... regional partnership designed to advance sports nutrition education, ... young athletes, scholastic athletes and their families across ... & Mind Initiative will offer a comprehensive and ... and mental dynamics involved in pursuing athletic excellence,” ...
(Date:8/28/2014)... 28, 2014 Valero Renewable Fuels Company, ... (NYSE: VLO), and the Ports of Indiana hosted Lt. ... today at a Port Appreciation and Welcome Celebration commemorating ... plant. , “The opening of Valero’s ethanol facility at ... economic development win for the State of Indiana,” Ellspermann ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Gurnick Academy ... MRI Technology program is re-accredited for the 5 years ... Resonance Imaging Technologists (ARMRIT). , “We are very ... constantly improving our program to make sure we provide ... lot of interest in MRI field nowadays and I ...
Breaking Medicine News(10 mins):Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... a blood vessel medication, improved distances 50% ... prescription drug naftidrofuryl eases leg cramps caused by ... farther, according to Belgian researchers. , They reviewed ... condition called intermittent claudication. Patients who took the ...
... Brain function and health will be the focus of the ... in San Francisco. Part of a highly recognized series, ... with the booming aging industry; factors that predict future cognitive ... participate in them. , WHO: , The program is sponsored ...
... On Sunday, June 29,2008, West Coast Bank will sponsor ... Run, Portland,s most unique 8k personal,challenge run., Race ... the,Burnside Bridge by 9:00 a.m. when the bridge rises. ... the Oregon Zoo and winds through the,paved roads of ...
... are estimated to be affected by the devastation caused ... by researchers from the Johns Hopkins Bloomberg School of ... Systems (GIS), the researchers calculated the likely distribution of ... developed maps of the regions at greatest risk from ...
... and Vancouver Coastal Health Research Institute have discovered how ... body and are working toward a treatment to block ... discovery, published today in the journal Cell Host and ... and its newly discovered counterpart protein in the human ...
... broader public action to curb effects , , WEDNESDAY, May 14 ... particulate matter air pollution can increase blood pressure and harm ... , The findings may explain why air pollution can trigger ... failure and stroke, the researchers said. , Particulate matter (PM) ...
Cached Medicine News:Health News:Common Drug Eases Leg Pain From Walking 2Health News:Estimated 3.2 million Burmese potentially affected by cyclone 2Health News:Vancouver researchers discover missing link between TB bacteria and humans 2Health News:Pollution Particles Impair Blood Vessel Function 2
96 channel Parallel dispenser using Positive Air Displacement Technology...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... The Labcyte Echo 550 compound ... droplets down to 5 nL using ... on focused acoustic energy. Monitoring of ... fluids enables the Echo 550 to ...
Medicine Products: